Literature DB >> 17165155

A missense germline mutation in exon 7 of the MSH2 gene in a HNPCC family from center-Italy.

Francesca Bianchi1, Eva Galizia, Emilio Porfiri, Laura Belvederesi, Romina Catalani, Cristian Loretelli, Raffaella Bracci, Italo Bearzi, Chiara Turchi, Alessandra Viel, Riccardo Cellerino.   

Abstract

INTRODUCTION: Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is an autosomal dominant inherited disease predisposing to the development of colorectal cancers and several other malignancies (endometrium, ovaries, stomach, small bowel, hepatobiliary and urinary tract). HNPCC is caused by germline mutations in any of the MisMatch Repair (MMR) genes. Mutations in MLH1 and MSH2 account for almost 90% of all identified ones. About 15% of mutations identified in MSH2 are missense ones. PATIENTS AND METHODS: We studied one family, fulfilling Amsterdam II criteria, referred to our Center for genetic counselling. The proband, and some of her relatives, have been investigated for microsatellite instability (MSI), immunohistochemical MMR protein staining and by direct sequencing and Multiplex Ligation-dependent Probe Amplification (MLPA).
RESULTS: All patients carried the same novel MSH2 germline missense mutation (R359S) in exon 7, which determines the substitution of an Arginine, which is a basic amino acid, with a polar Serine residue (R359S). The mutation was associated with lack of expression of MSH2 protein and high microsatellite instability in tumour tissues. The same mutation has been detected in one healthy relative.
CONCLUSIONS: The mutation here reported shows a high correlation with phenotype. The mutation is located in an evolutionary conserved domain. Taken together, our findings suggest evidence that the amino acid substitution can be interpreted as pathogenetic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17165155     DOI: 10.1007/s10689-006-9110-z

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  18 in total

Review 1.  Testing guidelines for hereditary non-polyposis colorectal cancer.

Authors:  Asad Umar; John I Risinger; Ernest T Hawk; J Carl Barrett
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

2.  Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer.

Authors:  P Peltomäki; H F Vasen
Journal:  Gastroenterology       Date:  1997-10       Impact factor: 22.682

3.  Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing.

Authors:  S Syngal; E A Fox; C Li; M Dovidio; C Eng; R D Kolodner; J E Garber
Journal:  JAMA       Date:  1999-07-21       Impact factor: 56.272

4.  Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors.

Authors:  V A Marcus; L Madlensky; R Gryfe; H Kim; K So; A Millar; L K Temple; E Hsieh; T Hiruki; S Narod; B V Bapat; S Gallinger; M Redston
Journal:  Am J Surg Pathol       Date:  1999-10       Impact factor: 6.394

Review 5.  Hereditary colorectal cancer syndromes.

Authors:  Lisa L Strate; Sapna Syngal
Journal:  Cancer Causes Control       Date:  2005-04       Impact factor: 2.506

6.  Mutations of hMLH1 and hMSH2 in patients with suspected hereditary nonpolyposis colorectal cancer: correlation with microsatellite instability and abnormalities of mismatch repair protein expression.

Authors:  Mario Scartozzi; Francesca Bianchi; Saverio Rosati; Eva Galizia; Annalisa Antolini; Cristian Loretelli; Andrea Piga; Italo Bearzi; Riccardo Cellerino; Emilio Porfiri
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 7.  Genetic predisposition to colorectal cancer.

Authors:  Albert de la Chapelle
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

8.  Pathogenicity of missense and splice site mutations in hMSH2 and hMLH1 mismatch repair genes: implications for genetic testing.

Authors:  M Cravo; A J Afonso; P Lage; C Albuquerque; L Maia; C Lacerda; P Fidalgo; P Chaves; C Cruz; C Nobre-Leitão
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

Review 9.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Authors:  C R Boland; S N Thibodeau; S R Hamilton; D Sidransky; J R Eshleman; R W Burt; S J Meltzer; M A Rodriguez-Bigas; R Fodde; G N Ranzani; S Srivastava
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

10.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

View more
  2 in total

1.  A germline missense mutation in exon 3 of the MSH2 gene in a Lynch syndrome family: correlation with phenotype and localization assay.

Authors:  Francesca Bianchi; Elena Maccaroni; Laura Belvederesi; Cristiana Brugiati; Riccardo Giampieri; Federica Bini; Raffaella Bracci; Silvia Pagliaretta; Michela Del Prete; Francesco Piva; Alessandra Mandolesi; Marina Scarpelli; Rossana Berardi
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

2.  An intronic mutation in MLH1 associated with familial colon and breast cancer.

Authors:  F Bianchi; M Raponi; F Piva; A Viel; I Bearzi; E Galizia; R Bracci; L Belvederesi; C Loretelli; C Brugiati; F Corradini; D Baralle; R Cellerino
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.